This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Amryt Pharma Yönetim

Yönetim kriter kontrolleri 3/4

Amryt Pharma CEO'su Joe Wiley, Jan2015 tarihinde atandı, in görev süresi 8.25 yıldır. in toplam yıllık tazminatı $ 1.72M olup, şirket hissesi ve opsiyonları dahil olmak üzere 43.4% maaş ve 56.6% ikramiyelerden oluşmaktadır. şirketin hisselerinin 1.1% ine doğrudan sahiptir ve bu hisseler $ 10.36M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.3 yıl ve 3.6 yıldır.

Anahtar bilgiler

Joe Wiley

İcra Kurulu Başkanı

US$1.7m

Toplam tazminat

CEO maaş yüzdesi	43.43%
CEO görev süresi	8.3yrs
CEO sahipliği	1.1%
Yönetim ortalama görev süresi	3.3yrs
Yönetim Kurulu ortalama görev süresi	3.6yrs

Son yönetim güncellemeleri

Güncelleme yok

Recent updates

Seeking Alpha • Oct 18

Amryt gets EMA panel nod for Mycapssa to retain orphan drug status in EU

A committee of the European Medicines Agency (EMA) recommended that the orphan disease designation to Amryt's (NASDAQ:AMYT) Mycapssa to treat acromegaly in the EU is maintained. Acromegaly is a disorder characterized by the pituitary gland producing too much growth hormone during adulthood. The bones in the hands, feet and face become bigger. The EMA's Committee for Orphan Medicinal Products (COMP) adopted the positive opinion. "The COMP recommendation to maintain the orphan disease designation for Mycapssa confirms the significant benefit of Mycapssa over the currently available injectable forms of somatostatin analogues, which represents a significant development for acromegaly sufferers in Europe," said Amryt CEO Joe Wiley. In September, EMA's Committee for Medicinal Products for Human Use (CHMP) had recommended the approval of Mycapssa as a maintenance therapy for certain patients with acromegaly. The orphan drug status in the EU provides for incentives, including 10 years' of market exclusivity for the drug, if approved.

Seeking Alpha • Sep 16

Amryt growth hormone disorder drug Mycapssa gets EMA panel nod for EU approval

A committee of the European Medicines Agency (EMA) recommended the approval of Amryt's (NASDAQ:AMYT) Mycapssa (octreotide capsules) in the EU as a maintenance therapy of acromegaly in patients who have responded to and tolerated treatment with octreotide or lanreotide. Acromegaly is a disorder characterized by the pituitary gland producing too much growth hormone during adulthood. The bones in the hands, feet and face become bigger. The decision of the EMA's Committee for Medicinal Products for Human Use (CHMP) was backed by data from a phase 3 trial called MPOWERED. The European Commission (EC), which generally follows the opinion of the CHMP, will now decide on the drug's approval. The EC decision is expected within within 67 days, the company said in a Sept. 16 press release. "The CHMP recommendation for approval of Mycapssa is a very significant development for acromegaly sufferers in Europe and Mycapssa would be the first and only oral somatostatin analog approved in the EU," said Amryt CEO Joe Wiley.

Seeking Alpha • Sep 08

Amryt gets British marketing approval & orphan drug designation for rare skin disease gel

Irish commercial-stage biopharma Amryt (NASDAQ:AMYT) on Thursday said UK's drug regulator had approved its Filsuvez gel to treat wounds associated with genetic skin disorder epidermolysis bullosa (EB). U.S.-listed shares of AMYT were 3.5% higher at $7.93 in premarket trading. The UK's Medical Healthcare & Products Regulatory Agency granted a marketing authorization and an orphan drug designation to Filsuvez for the treatment of partial thickness wounds associated with dystrophic and junctional EB in patients 6 months and older, AMYT said in a statement. "We look forward to continuing our discussions with the reimbursement agencies across the UK and European Union to begin delivering Filsuvez to treat patients as soon as possible...," AMYT CEO Joe Wiley said. The nod from the British regulator comes after the European Commission approved Filsuvez in Aug. The U.S. FDA rejected the company's approval application for Filsuvez in Feb., with Amryt (AMYT) later saying it would appeal the so-called complete response letter.

Seeking Alpha • Jul 14

Amryt stock rises 11% on FDA orphan drug status for Mycapssa for rare tumor condition

The U.S. Food and Drug Administration (FDA) granted orphan drug designation to Amryt's (NASDAQ:AMYT) Mycapssa to treat carcinoid syndrome (CS). CS occurs when a rare cancerous tumor called carcinoid tumor releases certain chemicals in the blood, causing several symptoms. According to the company CS is the most common functional syndrome associated with neuroendocrine tumours (NETs). Mycapssa (oral octreotide) is approved by the FDA as a long-term maintenance therapy for certain patients with acromegaly, a hormonal disorder which occurs when the pituitary gland produces too much growth hormone during adulthood. Amryt noted that its TPE platform enables the oral delivery of the octreotide molecule which is otherwise delivered as an injectable. The FDA grants orphan drug status to therapies that treat or prevent rare diseases that affect fewer than 200K people in the U.S. The designation provides certain incentives, including seven years of market exclusivity, if approved. AMYT +11.19% to $8.25 premarket July 14.

Seeking Alpha • Jun 23

Amryt's Filsuvez gets approval in EU to treat rare skin disorder

The European Commission (EC) approved Amryt's (NASDAQ:AMYT) Filsuvez to treat partial thickness wounds associated with dystrophic and junctional Epidermolysis Bullosa (EB) in patients 6 months and older. EB is a rare disease in which the skin becomes fragile and can tear or blister from minor injury/rubbing. Filsuvez will be the first and only approved therapy for patients EB, the Dublin-based company said in a June 23 press release. The approval was backed by data from a phase 3 trial called EASE which included 58 sites in 28 countries. The company noted that authorization of Filsuvez® in the EU provides a regulatory core dossier which may form the basis for future regulatory submissions in LATAM and the Middle East. A day ago, Krystal Biotech (KRYS) filed for U.S. approval of its topical gene therapy B-VEC to treat patients with dystrophic EB.

Seeking Alpha • Dec 09

Amryt Pharma: Advancing Novel Treatments For Rare And Debilitating Conditions

Amryt Pharma is developing and delivering innovative medicines for rare and debilitating conditions. The Company has acquired three companies since formation, and has commercialized three medicines. The Company also has a significant development pipeline.

CEO Tazminat Analizi

Joe Wiley'un ücretlendirmesi Amryt Pharma'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2022	n/a	n/a	-US$790k
Jun 30 2022	n/a	n/a	US$3m
Mar 31 2022	n/a	n/a	US$3m
Dec 31 2021	US$2m	US$747k	US$1m
Sep 30 2021	n/a	n/a	-US$88m
Jun 30 2021	n/a	n/a	-US$81m
Mar 31 2021	n/a	n/a	-US$92m
Dec 31 2020	US$2m	US$727k	-US$105m
Sep 30 2020	n/a	n/a	-US$87m
Jun 30 2020	n/a	n/a	-US$92m
Mar 31 2020	n/a	n/a	-US$87m
Dec 31 2019	US$1m	US$588k	-US$63m

Tazminat ve Piyasa: Joe 'nin toplam tazminatı ($USD 1.72M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 3.70M ).

Tazminat ve Kazançlar: Joe şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Joe Wiley (51 yo)

8.3yrs

Görev süresi

US$1,720,000

Tazminat

Dr. Joseph A. Wiley, also known as Joe, M.D. was the Founder of Amryt Pharma plc and serves as its Chief Executive Officer since 2015. He has been a Director at Amryt Pharma plc since April 19, 2016. Dr. W...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Joseph Wiley	CEO & Director	8.3yrs	US$1.72m	1.1% $ 10.4m
Rory Nealon	CFO, COO & Company Secretary	8.3yrs	US$939.00k	0.51% $ 4.8m
Elizabeth Jobes	Chief Compliance Officer	2.3yrs	Veri yok	Veri yok
John McEvoy	General Counsel	5.6yrs	Veri yok	Veri yok
Stephen Joyce	Head of Marketing & Head of APAC	4.3yrs	Veri yok	Veri yok
Julie Eastwood	Head of Human Resources	no data	Veri yok	Veri yok
Helen Phillips	Head of Medical Affairs	no data	Veri yok	Veri yok
Sheila Frame	President of Americas	2yrs	Veri yok	Veri yok
Tracy Cunningham	Chief Medical Officer	less than a year	Veri yok	Veri yok
Jordi Casals	President of EMEA Region	less than a year	Veri yok	Veri yok

3.3yrs

Ortalama Görev Süresi

54.5yo

Ortalama Yaş

Deneyimli Yönetim: AMYT 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Joseph Wiley	CEO & Director	7yrs	US$1.72m	1.1% $ 10.4m
Stephen Wills	Independent Non-Executive Director	3.6yrs	US$88.00k	0.023% $ 220.5k
Alain Munoz	Independent Non-Executive Director	3.6yrs	US$58.00k	0.0070% $ 66.1k
Patrick V. J. Vink	Independent Non-Executive Director	3.6yrs	US$60.00k	0.0078% $ 73.5k
Donald Stern	Independent Non-Executive Director	3.6yrs	US$80.00k	0% $ 0
Raymond Stafford	Independent Non-Executive Chairman of the Board	7yrs	US$88.00k	0.61% $ 5.8m
Roni Mamluk	Independent Non-Executive Director	1.7yrs	US$20.00k	0% $ 0
George Hampton	Independent Non-Executive Director	3.6yrs	US$65.00k	0.031% $ 294.0k
Raj Kannan	Independent Non-Executive Director	1.7yrs	US$20.00k	0% $ 0

3.6yrs

Ortalama Görev Süresi

59yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: AMYT 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.6 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2023/04/14 22:03
Gün Sonu Hisse Fiyatı	2023/04/11 00:00
Kazançlar	2022/09/30
Yıllık Kazançlar	2021/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Amryt Pharma plc 8 Bu analistlerden 4, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Michelle Gilson	Canaccord Genuity
Brandon Folkes	Cantor Fitzgerald & Co.
Andrew Young	Davy